VIP (Vasoactive Intestinal Peptide) 10mg

VIP Peptide Research Findings in Preclinical Models

This product is not intended for weight loss, human consumption, or veterinary use. It is sold for research purposes only. Please handle with care and follow all safety guidelines for the specific chemicals involved.

1. Behavioral and Ingestive Regulation Studies
   Intracerebroventricular (ICV) administration of VIP in rats decreases resting behavior and increases activities like rearing and standing. At higher doses, it suppresses drinking and feeding. Systemic administration (intraperitoneal, IP) of VIP can also influence ethanol intake and feeding behavior, suggesting that VIP modulates ingestive and reward-related behavior. (PubMed)
2. Neuroprotection in Parkinson’s Disease Models
   In rats lesioned with 6-hydroxydopamine (6-OHDA) to mimic Parkinson’s disease, systemic VIP (25 ng/kg IP every other day for ~15 days) restored reduced GABA levels in the ventral anterior thalamus (VATh), increased NGF-immunoreactive mast cells, and ameliorated some motor deficits (though not all dopaminergic cell loss). This suggests VIP’s protective effects might involve modulation of GABAergic transmission and neurotrophic support. (PubMed)
3. Memory and Cognitive Effects
   VIP can counteract spatial memory deficits induced by scopolamine in rats, when administered via i.p., subcutaneous (s.c.), or ICV routes. The effect exhibits a bell-shaped dose-response curve. VIP injected into the hippocampal CA1 region also improved learning and memory in a depression model (bilateral olfactory bulbectomy), particularly when injected into the right CA1. (PubMed)
4. Smooth Muscle and Physiological Responses
   In gastric smooth muscle preparations from rat stomachs, VIP dose-dependently inhibits contractions induced by cholinergic stimulation (e.g. carbachol), but not those elicited by high KCl or caffeine. VIP’s effect is related to modulation of calcium handling, particularly affecting extracellular calcium influx. (PubMed)
5. Anatomical and Neurochemical Distribution
   VIP is widely expressed in the rat brain: immunoreactive cell bodies and fibers are found in cortex, hippocampus, amygdala, suprachiasmatic nucleus (SCN), brainstem nuclei, the stria terminalis, etc. It often co-localizes with GABA in certain amygdalar cell populations. (PubMed)

Research Implications and Considerations:

• Dose and route matter: VIP’s effects often differ depending on how it is administered, the region targeted, and the dose; for many behaviors there is a non-linear (e.g. bell-shaped) response curve.
• Neuroprotection vs neurotransmitter modulation: Some of VIP’s effects appear due to its action on nonneuronal cells (e.g. mast cells) releasing growth factors (NGF), while others appear to directly modulate neurotransmission (GABA, dopamine).
• Lateralization: Some studies show differences between left vs right hippocampus in how VIP peptide influences behavior in models of depression.
• Research models: The neuroprotective and cognitive effects of VIP observed in preclinical studies suggest its continued investigation in research models of neurodegenerative disease, cognitive function, and mood-related pathways.

Product Specifications Table

Handling, Reconstitution and Storage

• Store lyophilized VIP peptide at 4C. For long-term storage freeze at -20C.
• Reconstitute with bacteriostatic water under aseptic conditions
• Use the NuScience Peptide Calculator to determine the correct BAC water volume for your target research concentration
• Once reconstituted, use promptly or store refrigerated
• For comprehensive storage protocols, refer to the NuScience Peptide Handling and Storage guide
• This product is for laboratory research use only. Not for human consumption.

Conclusion

NuScience Peptides supplies VIP (Vasoactive Intestinal Peptide) for sale in 10mg lyophilized vials at 99%+ purity for laboratory research use only. Third-party Certificates of Analysis are available on the NuScience Lab Test Results page.

Representative References

Here are three PubMed references in APA format:

• Del Valle, A., Van Der Ploeg, L. H. T., & Gall, C. M. (1989). VIP-like immunoreactivity in rat brain: evidence for a major pathway linking the amygdala and hypothalamus via the stria terminalis. The Journal of Neuroscience, 9(2), 540-553. (PubMed)
• Mohseni, S., Reisi, P., & Maghsoudi, N. (2011). Lateralized hippocampal effects of vasoactive intestinal peptide on learning and memory in rats in a model of depression. Behavioural Brain Research, 224(1), 122-128. (PubMed)
• Sommer, S., Stalder, H., Guth, P., & Mündermann, L. (1996). Vasoactive intestinal peptide (VIP) treatment of Parkinsonian rats increases thalamic gamma-aminobutyric acid levels and alters the release of nerve growth factor by mast cells. Brain Research, 739(1-2), 100-110. (PubMed